key: cord-0755654-3114a2vx
authors: Strope, Jonathan D.; Chau, Cindy H.; Figg, William D.
title: Are Sex Discordant Outcomes in COVID-19 Related to Sex Hormones?
date: 2020-06-17
journal: Semin Oncol
DOI: 10.1053/j.seminoncol.2020.06.002
sha: 98ce754c603dce75e5fc9aadbb86489f03bf853c
doc_id: 755654
cord_uid: 3114a2vx

COVID-19 has a clear sex disparity in clinical outcome. Globally, infection rates between men and women are similar; however, men are more likely to have more severe disease and are more likely to die. The causes for this disparity are currently under investigation and are most likely multifactorial. Sex hormones play an important role in the immune response with estrogen seen as immune boosting and testosterone as immunosuppressing. Additionally, an important protease involved in viral entry, TMPRSS2, is regulated by androgens. Many observational and prospective studies are ongoing or initiating to further examine the role of sex hormones in SARS-CoV-2 infection and if modulation of them is a realistic treatment option.

Global epidemiological data have revealed sex discordant severity of disease and outcomes in patients with COVID-19 infections with males fairing FAR worse than females. 1 Many hypotheses have been put forward to explain this difference such as smoking, age, and co-morbid conditions. 2,3 . These include differences in immune responses between the sexes. Estrogen and testosterone are both known to mediate immune responses, with testosterone an immune suppressor and estrogen an immune booster. A previous study has reported that SARS-CoV-2 entry into the host cell depends on the angiotensin converting enzyme (ACE) 2 receptor and cellular protease TMPRSS2. ACE2 is the cellular receptor that the SARS-CoV-2 spike protein binds to while TMPRSS2 is a serine protease that cleaves the S protein for viral priming. 4 TMPRSS2 expression is regulated in part by androgens and is a known biomarker of prostate cancer severity when fused with ERG. 5, 6 This data brings questions to the forefront about the role sex hormones play in disease susceptibility and severity and whether their modulation could serve as a viable treatment option for SARS-CoV-2 infection. In addition, studies aimed at finding clinically relevant biomarkers to stratify outcome are important in resource limited settings, like those found in pandemic epicenters. Intense research efforts are currently underway to investigate the association of sex hormones and ACE2/TMPRSS2 expression with COVID-19 severity as well as exploit inhibitors that target the sex steroid hormone pathway or modulate TMPRSS2 expression/activity as potential treatment options for the disease.

Sex hormones play an important and dimorphic role in immune regulation and response. This difference is seen in both innate and adaptive immunity. Estrogen has been shown to enhance immunological markers and response. 7 Estrogen is also linked to T-cell proliferation. 7 In addition, X chromosome linked genes play a role in the heightened response of females. Females are known for a greater presence of autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus. Testosterone is seen as an immunosuppressive agent by down-regulating natural killer cells and tumor necrosis factoralpha. 7 Often, over the course of an infection, females mount a more robust response. While this response can be effective in clearing the infection quicker, it can also contribute to immunopathological issues. Sex differences in immune response are directly attributed to the prevalence, severity, and outcomes of viral infections. 8, 9 Notably, as with SARS-CoV-2, epidemiological data for MERS-CoV and SARS-CoV showed a similar trend toward worse outcomes in men. 10, 11 (Table 1) TMPRSS2 and ACE2 are co-expressed in tissues targeted by SARS-CoV-2

Co-expression of TMPRSS2 and ACE2 is found in the ciliated and secretory cells of the nasal cavity, providing important information on means of transmissibility. Expression is also observed in the ciliated and secretory cells of the lungs. 12, 13 Clinical reports note that infection of type-2 pneumocytes in the lower respiratory track is important in the development of severe lung symptoms. 14 However, coexpression also occurs in many tissues outside the lungs, providing alternative sites for viral infection (Figure 1) . These areas include the eyes, esophagus, heart, ileum, colon, gallbladder, brain, testes, and prostate. 12, 15 It is known that TMPRSS2 expression is upregulated by androgens in prostate cancer cell lines and in vivo. 16, 17 Important questions remain to be answered regarding the effect of androgens on the expression of both ACE2 and TMPRSS2 in the lungs and other tissues vulnerable to viral infection. In a preprint study, researchers concluded that TMPRSS2 expression in lungs was not mediated by androgens or by enzalutamide, an agent that decreases androgen receptor signaling. 18 It may be that the cell types must be separated to see the effect as there is co-expression in club cells of the prostate and lungs. 19 Additionally, are other hormones involved in modulation of TMPRSS2 expression? Estrogen is known to regulate the TMPRSS2-ERG fusion in prostate cancer 20 , however, its role outside of prostate cancer and this fusion is unknown. Studies are also ongoing to evaluate the association of genetic polymorphisms and/or mutations that cause disparate expression of TMPRSS2 and ACE2 with COVID-19related outcomes. A recent development is that TMPRSS2 may be circulating and able to act on cells without membrane expression. 21 It has been reported that prostate cancer cell lines in vitro and in vivo shed the protease. 22 Whether soluble TMPRSS2 is involved in mediating viral infection is an interesting concept that warrants further study. 23

If sex hormones play an important role in the disparity of COVID-19 outcomes, then correlative studies can be conducted across various patient populations to investigate for associations with abnormal hormone levels or genetics. In men and women, hypogonadism, or the inability to properly produce sex hormones, can be split into two types, hypergonadotrophic hypogonadism and hypogonadotrophic hypogonadism. The former is characterized by dysfunction at the primary gonads whereas the latter results from a dysfunction of the pituitary or hypothalamus. Some examples are Prader-Willi syndrome, Turner syndrome, and Klinefelters syndrome. 24 The specific abnormality, low testosterone or low estrogen, will determine the hypothesized outcome in relation to COVID-19. Additionally, men undergoing androgen deprivation therapy (ADT) and women on hormone therapy for various forms of cancer may have lower hormone levels than normal. On the other side, patient populations with increased levels of sex hormones can also be observed. In men, these include individuals taking testosterone replacement therapy and men with a genetic predisposition to higher testosterone or androgen receptor signaling (androgenic alopecia, benign prostatic hyperplasia 25 ). Females with polycystic ovary syndrome have increased androgen levels and have been proposed as a sub-group to observe. 26 If sex hormones play an important role, these patient populations represent groups that may have outcomes different from matched individuals of the same sex. It is not known at which stage of infection these hormones may affect outcomes. Notably, two preprint studies have analyzed sex hormone levels in men presenting to or in hospital care for COVID-19. They found that testosterone levels are decreased and gonadal function is altered. 27 28 It is possible that as the disease progresses, the viral infection begins to affect testosterone levels. Knowing the timing of this event is important in understanding where in the course of infection androgen levels determine outcome. In a recent preprint study, analysis of clinical data on patients with COVID-19 from the UK Biobank and Yale New Haven Hosptial identified an association between androgen imbalance and disease complicatios in male patients. 29

Androgenic alopecia (AGA) is a clinical condition that affects men and is regulated by androgens and androgen receptor expression. AGA is considered the most common cause of male pattern hair loss. The idea to look for AGA in men suffering with COVID-19 was first proposed by Goren et al. 26 They hypothesized that men diagnosed with AGA would represent a population with higher androgen and androgen signaling. In a study of preliminary observations in Spain, 71% (29 of 41) of men diagnosed with COVID-19 related bilateral pneumonia were also diagnosed with androgenic alopecia. 30 In a followup report, the researchers have expanded their patient population to 175 hospital admitted COVID-19 positive men and women. During the course of the study, men accounted for a majority of those admitted (122/175) and 79% of them had observed AGA using the Hamilton-Norwood scale for men and the Ludwig scale for females. 31 What these studies are missing, and what future studies could benefit from are robust clinical laboratory values for sex hormones over the course of the disease.

Hormone therapy for prostate cancer, also called androgen deprivation therapy (ADT), refers to treatments that block the production or use of androgens. ADT is the mainstay of treatment for prostate cancer and is used to reduce testosterone production in the testicles to prevent androgen-mediated tumor growth. ADT includes agonists and antagonists of upstream hormones that control androgen release such as LHRH agonists (leuprolide, goserelin, triptorelin, histrelin) and LHRH antagonists (degarelix). ADT is often continued until disease progression or death. First-generation antiandrogens (flutamide, bicalutamide, and nilutamide) are receptor antagonists that target AR translocation and subsequent AR signaling. Second-generation antiandrogens inhibit pathways involved in persistent androgen production or AR signaling from residual androgens produced in extragonadal sources and include biosynthesis inhibitors (abiraterone, a CYP17 inhibitor) and next generation AR antagonists (enzalutamide, apalutamide, darolutamide). 32 ADT has been shown to decrease the risk of autoimmune disorders and has been proposed as a treatment option in these disorders. 33 

Clinical trials have been initiated worldwide aimed at targeting sex hormone pathways or TMPRSS2 directly and these are summarized in Table 3 . Each trial has different primary and secondary endpoints relative to the drug they are using and rationale. At the time of writing, there are nine studies in various stages that utilize direct or indirect inhibitors of TMPRSS2. Two direct TMPRSS2 inhibitors are camostat and nafamostat, both of which are approved in Japan for pancreatitis. 4, 35 The third is an expectorant called bromhexine. 17 The rationale for the 9 clinical trials testing these direct TMPRSS2 inhibitors is that inhibition of the protease activity of TMPRSS2 will prevent viral entry. Some of these studies are in combination with hydroxychloroquine that has been shown to be effective in vitro against SARS-CoV-2. 36 Indirect modulators of TMPRSS2 attempt to block the sex steroid hormone pathway. A trial is investigating the protective and immunomodulatory effects of estrogen in reducing the severity of COVID-19 outcomes in both male and female patients (NCT04359329). Similar in concept to the estrogen study is a trial assessing the safety and efficacy of progesterone for the treatment of COVID-19 in hospitalized men to examine the drug's anti-inflammatory properties to dampen the cytokine storm observed in SARS-CoV-2 infection. Somewhat contrary to the studies and rationale discussed is a study that is investigating tamoxifen in combination with isotretinoin as a treatment (NCT04389580). The study rationale is that isotretinoin decreases ACE2 expression and tamoxifen is involved in vesical transport, cellular pH, prevention of lung fibrosis, and reduction of serum TGFβ-1 levels. Not mentioned is the potential effects of tamoxifen on testosterone and estrogen. 37, 38 In men treated with tamoxifen, an increase in testosterone was observed clinically. 37 Recently added to Clinicaltrials.gov is a study titled HITCH (NCT04397718), detailed in a press release from the Veterans Administration. 39 HITCH will enroll hospitalized Veterans to be given degarelix, a LHRH antagonist. Degarelix will be used to suppress testosterone production and potentially reduce viral burden by decreasing TMPRSS2 expression. A phase 2, randomized, open-label study at Johns Hopkins will be evaluating bicalutamide vs standard of care in patients with COVID-19 requiring inpatient hospitalization (NCT04374279) to determine if bicalutamide improves the time to clinical improvement. Bicalutamide can not only suppress androgen activity but also raise estrogen levels which has been shown to have protective effects against acute lung injury. 40 Lastly, there is a study to evaluate the effects of spironolactone on oxygenation in COVID-19 patients with acute respiratory distress syndrome (NCT04345887). Spironolactone is a steroid that blocks the hormone aldosterone and has been known to have moderate anti-androgenic properties with some estrogen-like effects. 41 It is expected that many more trials will be launched as observations and results are reported.

At the time of writing, we are aware of two additional studies being planned in Europe to evaluate enzalutamide in patients with COVID-19; these trials are not yet registered with Clinicaltrials.gov. In silico drug screening efforts have identified the androgen-AR signaling axis, specifically 5-alpha reductase inhibitors (dutatsteride and finasteride), involved in modulating both ACE2 and TMPRSS2 levels, making these compounds potential drug candidates for futher investigation. 29 In recent study, abiraterone was shown to inhibit in vitro SARS-CoV-2 activity, demonstrating another potential treatment for COVID-19. 42 The scientific community is racing against time in search of a cure for COVID-19 and collaborative efforts are called upon to gather as much data and samples as possible to elucidate the sex disparity observed in disease outcomes. 43 A recent study of abiraterone demonstrated the ability to decrease viral load by about 70%. This data may be used to initiate a study of abiraterone in the near future. 42

As the pandemic continues, important questions must be answered to elucidate the reasons some individuals are affected more severely than others. This data has many implications. First, as governments begin to reopen after lockdowns, a major strategic point is to continue to sequester the populations that are most vulnerable. Next, knowledge of who may progress to severe disease can help health care officials know where to mobilize resources. As seen in many of the most-affected communities, limited resources in overrun hospitals lead to worse outcomes. Finally, underlying differences in outcome may inform researchers on potential therapeutic targets. Manipulation of genes and pathways important to viral replication and spread are hallmarks of anti-viral treatment. We don't yet know if SARS-CoV-2 will reemerge or become a seasonal threat. The more information we gather now the better prepared we will be to deal with similar infections in the future.

This work was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the US government. 

Gender Differences in Patients With COVID-19: Focus on Severity and Mortality

Sex Differences in Mortality from COVID-19 Pandemic: Are Men Vulnerable and Women Protected? JACC Case Rep

Sex difference and smoking predisposition in patients with COVID-19

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer

Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases

Sex Drives Dimorphic Immune Responses to Viral Infections

The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health

Do men have a higher case fatality rate of severe acute respiratory syndrome than women do?

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells

Pathogenesis of COVID-19 from a cell biology perspective

The scRNA-seq expression profiling of the receptor ACE2 and the cellular protease TMPRSS2 reveals human organs susceptible to COVID-19 infection

Dual targeting of the androgen receptor and hypoxiainducible factor 1alpha pathways synergistically inhibits castration-resistant prostate cancer cells

The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis

No evidence that androgen regulation of pulmonary TMPRSS2 explains sex-discordant COVID-19 outcomes

Expression of ACE2, the SARS-CoV-2

Receptor, and TMPRSS2 in Prostate Epithelial Cells

Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues

Catalytic cleavage of the androgen-regulated TMPRSS2

protease results in its secretion by prostate and prostate cancer epithelia

TMPRSS2: Potential Biomarker for COVID-19 Outcomes

Etiology and treatment of hypogonadism in adolescents

Androgen receptor roles in the development of benign prostate hyperplasia

What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy

The majority of male patients with COVID-19 present low testosterone levels on admission to Intensive Care in

Effect of SARS-CoV-2 infection upon male gonadal function: A single center-based study

Androgen Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men

A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain -A potential clue to the role of androgens in COVID-19 severity

Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients -the "Gabrin sign

Androgen deprivation and immunotherapy for the treatment of prostate cancer

Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases

Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532)

Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

The Role of Estrogen Modulators in Male Hypogonadism and Infertility

Changes in serum estrogen levels in women during tamoxifen therapy

VA scientists race to determine effectiveness of prostate cancer drug in treating COVID-19 patients

17beta-estradiol protects the lung against acute injury: possible mediation by vasoactive intestinal polypeptide

Antiandrogenic effect of spirolactones: mechanism of action

Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system

SARS-CoV-2, Testosterone and frailty in males (PROTEGGIMI): A multidimensional research project

Drug Name Target